CI-8993

CI-8993 (JNJ-61610588) is a monoclonal antibody (fully human IgG1 kappa) from ImmuNext, with Curis as partner and Janssen as partner. A monoclonal antibody designed to block signalling through VISTA (V-domain Ig suppressor of T cell activation). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in 2 studies linked below. Curis's phase 1 (NCT04475523) is completed; Curis deprioritised it in November 2022 and did not exercise its option; rights reverted to ImmuNext in January 2024 (Curis 10-K for 2023). Janssen's earlier phase 1 as JNJ-61610588 (NCT02671955) was terminated. No current development found. Whether it works in people has not been established unless a trial below reports it.